Blood test for lung cancer detection using nucleosome analysis
Differentiating Benign and Malignant Pulmonary Nodules Using Epigenetically Modified Nucleosomes in Plasma
This study is testing a new blood test called Nu.Q to see if it can accurately detect lung cancer in people from Taiwan compared to traditional CT scans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06838806 on ClinicalTrials.gov |
What this trial studies
This study evaluates the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population, comparing its performance with low-dose computed tomography (LDCT). It involves collecting 20 mL of blood from participants undergoing chest LDCT/CT, isolating plasma for Nu.Q analysis, and correlating results with lung cancer pathology findings. The study aims to enroll 500 participants to validate the test's effectiveness and explore its potential role in lung cancer prevention and survival outcomes.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 20 or older with lung nodules ≥ 6mm identified through a chest CT scan and assessed as high-risk by a physician.
Not a fit: Patients who are pregnant or assessed as unsuitable for thoracic surgery or biopsy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a more accurate and convenient blood-based screening tool for early lung cancer detection.
How similar studies have performed: Previous studies have shown promising results for similar blood-based tests in detecting early lung cancer, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 20 or older * Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm * Individuals understand the content of the consent form and are willing to participate in this study. * The lung nodule is assessed by a physician as high-risk, requiring thoracic surgery or biopsy for diagnosis Exclusion Criteria: * Pregnant women * Individuals without capacity for consent, unable to understand the content of the consent form, or unwilling to participate in this study * Assessed by a physician as unsuitable for thoracic surgery or biopsy for diagnosis
Where this trial is running
Taipei
- National Taiwan University — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Pei-Hsing Chen, MD
- Email: chenph@ntu.edu.tw
- Phone: 886-2-2312-3456 Ext. 53422
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.